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Abstract
Hepatitis B vaccination is recommended for men who have sex with men (MSM) in many
countries, but information on vaccine coverage is scarce. We studied hepatitis B vaccination pro-
grammes and coverage among MSM in Europe to guide prevention. From a large (N = 174 209)
pan-European MSM survey (EMIS-2010), we used data on self-reported hepatitis B vaccin-
ation, age, education, settlement size and disclosure of the same-sex sexual orientation
(‘outness’). We excluded participants with a history of hepatitis B. In multilevel (participants,
countries) logistic regression models, we calculated adjusted odds ratios (aOR) with 95% con-
fidence intervals (95% CI). We analysed data of 163 987 MSM in 38 European countries:
38.3% were ‘out’ to all or almost all, 56.4% reported vaccination against hepatitis B and
65.5% lived in countries with free recommended hepatitis B vaccination for MSM. In the
final model the odds for being vaccinated increased with outness (‘out to all or almost all’:
aOR 1.76, 95% CI 1.70–1.83 vs. ‘out to no one’) and with living in countries, where hepatitis
B vaccination was recommended and free-of-charge for MSM (aOR 2.21, 95% CI 1.47–3.32 vs.
‘no or unclear recommendation’). To increase hepatitis B vaccination coverage among MSM,
implementation of MSM-specific recommendations and improvement of the societal climate
for MSM is needed.
Introduction
Hepatitis B vaccines have been available since the early 1980s and in 1992 the World
Health Assembly called for the inclusion of hepatitis B vaccination in all national vaccin-
ation guidelines [1]. Almost all European countries responded by setting up universal
programmes for the general population including childhood vaccination and/or targeted
programmes for indication groups like men who have sex with men (MSM) and people
with frequently changing sexual partners [2]. Sexually transmitted infections with hepatitis
B were common among MSM before vaccination programmes were introduced [3]. A sys-
tematic review from 2013 concluded that hepatitis B surface antigen (HBsAg) prevalence
in MSM was on average 22 times higher than that in the general population [4]. A more
recent review, published in 2018, calculated HBsAg prevalences among MSM between
0.0% and 1.4%, based on estimates from six European countries [5]. Although below
2%, which implies low prevalence, the authors still considered MSM a priority group
for immunisation.
Many European countries have issued MSM-specific recommendations, typically including
coverage of vaccination costs. However, vaccination coverage might be influenced not only by
national vaccination guidelines but also by the ability of health care systems to identify and
reach vulnerable populations, respectively the willingness of MSM to disclose the same-sex
sexual contacts to a health care provider and to ask for vaccination. The circumstances allow-
ing MSM to disclose their sexuality and other socio-demographic parameters are crucial for
vaccine uptake [6]. Younger age, gay sexual identity and higher socioeconomic status are
among the factors positively associated with hepatitis B vaccination coverage in MSM [7].
We analysed how national hepatitis B vaccination strategies and socio-demographic
factors like age, educational level, settlement size and the disclosure of the same-sex sex-
ual orientation affect hepatitis B vaccination coverage of MSM in Europe. With our
results we want to help identify gaps in vaccination coverage and guide public health
measures.
Methods
For this paper we used data from following sources: EMIS-2010 provided data on vaccination
coverage among MSM across 38 European countries. We also used four sociodemographic
variables. We further collected information on vaccination programmes (universal and
targeted) through online literature research and a short survey.
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Dataset
The 2010 European MSM Internet Survey (EMIS-2010) was an
open-access online questionnaire which was available from 6
June to 31 August 2010. The survey reached 181 434 men in 46
countries [8]. It was a multi-lingual, pan-European, cross-
sectional sexual health needs assessment for MSM, including
measures of risk and precautionary behaviours, history of sexually
transmitted infections and access to healthcare services [9]. Data
collection and recruitment of participants for EMIS-2010 had
the goal to capture a large and diverse sample of MSM across
Europe [10].
The detailed survey development and methods of EMIS-2010
are described elsewhere [9]. We excluded men from countries
with less than 100 qualifying cases, and men living in Oversea
Departments, Territories and Collectivises of France, in British
Overseas Territories and Crown Dependencies, or in Greenland
(n = 446). Furthermore, we excluded cases who answered in
more than one place in logically inconsistent ways (n = 6779).
This resulted in a final dataset of 174 209 eligible participants
living in 38 European countries.
Hepatitis B immunisation status
Men participating in EMIS-2010 were asked ‘Have you been vac-
cinated against hepatitis B?’ and the following answers were
possible:
(1) No, I am naturally immune to hepatitis B (because I had it in
the past)
(2) No, and I don’t know if I’m immune
(3) Yes, and I completed the course of three shots of vaccine
(4) Yes, but I did not complete the course of three shots of
vaccine
(5) Yes, but I did not respond to the vaccinations
(6) I don’t know
We combined the three options starting with ‘Yes’, calling it
‘History of hepatitis B vaccination’. Men who answered ‘No,
and I don’t know if I’m immune’ (2), ‘I don’t know’ (6), as well
as missing answers, were coded as ‘No history of hepatitis B vac-
cination’. Men who answered ‘No, I am naturally immune to
hepatitis B (because I had it in the past)’ (1) were excluded
from further analyses, leading to an analytic sample of 163 987
participants. We performed a sensitivity analysis with missing
answers and ‘I don’t know’ excluded.
Four socio-demographic variables were used for analyses: age
group (according to quartiles: <25 years (q1), 25–39 years (q2 + 3),
40 + years(q4)); educational level (low: ISCED 1 + 2
(International Standard Classification of Educational Degrees
1997), medium: ISCED 3 + 4, high: ISCED 5 + 6); settlement
size (medium-sized and smaller settlements: <500 000 inhabi-
tants, big to very big cities: 500 000 or more inhabitants) and out-
ness, i.e. the disclosure of the own sexual orientation to friends,
family members and work/study colleagues (out to no one, a
few, less than half, more than half, all or almost all). The variables
were chosen prior to initiation of analyses and decisions were
based on factors associated with the outcome that were found
in previous studies [7, 11].
EMIS-2010 was approved by the Research Ethics Committee of
the University of Portsmouth, United Kingdom (REC application
number 08/09:21).
Vaccination programmes
We conducted a literature search on targeted vaccination pro-
grammes for hepatitis B in the 38 European countries included
in EMIS-2010. Reports and studies that contained information
on national hepatitis B vaccination recommendations for indica-
tion groups like MSM or people with frequently changing sexual
partners were extracted. When available, we also collected data on
year of implementation and how vaccination costs were met.
Additionally, we created a short survey and sent it to public health
authorities in each of the 38 EMIS countries. It consisted of three
items: whether a vaccination recommendation for MSM or people
with frequently changing sexual partners existed, with the option
for year of implementation; how costs were met in case a vaccin-
ation recommendation existed; whether there was any other rele-
vant information on the national hepatitis B vaccination
programme for key populations.
We used data from all available sources that were published up
to 2018 and grouped countries according to consistency of results:
‘Clear MSM-specific vaccination recommendation’ when there
were more positive than negative data sources. ‘Unclear’ when
there were as many positive as negative sources and ‘No vaccin-
ation recommendation for MSM’ when we found more negative
than positive sources. We combined the latter two groups to
‘No or unclear vaccination recommendation for MSM’.
Taking into account vaccination costs, countries in group
‘Clear MSM-specific vaccination recommendation’ were assigned
to ‘Free vaccination for MSM’, ‘Co-payment required’ or ‘Full
out-of-pocket payment required’. We combined the latter two
groups to ‘MSM-specific vaccination recommendation with pay-
ment’. This resulted in an outcome ‘MSM-specific vaccination
recommendation’ with three values for analyses: ‘Free vaccination
for MSM’; ‘MSM-specific vaccination recommendation with pay-
ment’ and ‘No or unclear vaccination recommendation for MSM’.
Through online research we also collected data on national
vaccination guidelines for the general population. For each coun-
try we extracted information on existing and former universal
vaccination programmes, year of implementation and age groups
that were reached in the year 2010, when EMIS took place. For
analyses we created the variable ‘General vaccination programme’
that included participants who were possibly vaccinated as
infants, children or adolescents.
Statistical analyses
We performed descriptive analyses at the country level for hepatitis
B vaccination status, age group, educational level, settlement size and
outness and reported frequencies and proportions. Categorical
variables were compared by the χ2 test. A P-value < 0.05 was consid-
ered statistically significant.
Univariable and multilevel (participants, countries) logistic
regression analyses with outcome ‘hepatitis B vaccination history’
and country of residence as group variable were conducted.
Variables associated with the outcome in univariable analysis at
P-value < 0.05 were included in multivariable models. Stepwise
forward model selection with independent variables age group,
educational level, settlement size, MSM-specific vaccination rec-
ommendation and general vaccination programme was applied
in order to find the best fitting model. It was assessed by likeli-
hood ratio tests and P-values < 0.05 were considered statistically
significant. Total numbers, odds ratios (OR), 95% confidence
intervals (95% CI) of OR and the intraclass correlation coefficient
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(ICC) were calculated. We computed additional models including
interactions between variables, but chose a multivariable model
without interactions for the presentation of results.
Results
Hepatitis B immunisation status
Overall, 44.7% of EMIS participants completed the full course of
three doses (Table 1). Malta had the highest proportion of fully
vaccinated participants (62.2%), followed by Austria (56.2%)
and Switzerland (54.7%). Lowest proportions were found in
Ukraine (12.8%), Serbia (13.5%) and Lithuania (14.6%). An
incomplete course was reported by 6.8% of participants. The
least common answer was ‘Yes, but I didn’t respond to the vaccin-
ation’ (1.6%). Of all participants, 22.9% answered ‘No, I’m not
vaccinated against hepatitis B and I don’t know if I’m immune’.
Countries with the highest proportion of not vaccinated men
were Slovenia (45.7%), Lithuania (45.2%) and Slovakia (42.2%).
The third most common answer was ‘I don’t know’ or missing
(18.1%). In some countries it was the leading answer with
Belarus (47.7%), Moldova (45.3%) and Bulgaria (41.4%) on the
top. In total, 5.9% of participants answered ‘No, I am naturally
immune to hepatitis B (because I had it in the past)’. Results of
self-reported vaccination rates on the country-level are shown in
Table 1.
Vaccination programmes
We identified three sources for targeted vaccination programmes:
the European Centre for Disease Prevention and Control (ECDC)
[12], the Vaccine European New Integrated Collaboration Effort
(VENICE) [13] and the European Liver Patients Association
(ELPA) [14]. For 18 countries, we found additional sources on
their vaccination programmes for indication groups MSM or peo-
ple with frequently changing sexual partners [15–32].
Furthermore, contact persons from 34 European countries
answered our short survey. In 28 cases, they confirmed the results
of collected data from literature research. Results are summarized
in Table 2.
In 21 of 38 European countries clear vaccination recommen-
dations for MSM or people with frequently changing sexual part-
ners were in place, 12 countries had no vaccination
recommendations for MSM and in five countries the situation
was unclear. These 17 countries together were coded ‘No or
unclear vaccination recommendation for MSM’ for analysis.
ELPA, VENICE and our short survey contained additional
information on the way how vaccination costs were met for the
21 countries with clear recommendations. Figure 1 shows a
map with the classification of all 38 countries according to com-
bined data.
Identified data sources for general vaccination programmes
were a review by Lernout et al. [2] and the websites of ECDC
and the World Health Organization (WHO). Only 6 of 38 inves-
tigated countries (Denmark, Finland, the Netherland, Norway,
Sweden and the UK) had not yet implemented universal hepatitis
B vaccination programmes in 2010, when EMIS data was collected
(Supplementary Table S1). In 29 countries universal programmes
for infants or new-borns were in place, in three countries for ado-
lescents or children. Additional programmes for adolescents,
adults or children had been active in 12 countries. Due to the
age of the 163 987 participants in the final dataset, only 20 660
(12.6%) men were possibly affected by universal vaccination
programmes.
Statistical analyses
In the sample included in further analysis (n = 163 987), that does
not contain men who were naturally immune, 92 440 (56.4%)
reported a positive vaccination history and 71 547 (43.6%)
reported no history of vaccination. Their characteristics regarding
age group, educational level, settlement size, outness, MSM vac-
cination recommendation and general vaccination programme
are displayed in Table 3.
Multivariable analysis
The outcome ‘vaccination history’ was positively associated with
age between 25 and 39 years, higher educational levels, living in
big to very big cities and increasing outness (Table 4). In countries
that had an MSM vaccination recommendation in place, chances
for participants to have positive vaccination histories were about
doubled for vaccination with payment (OR 1.96, 95% CI 1.26–
3.06) and for free vaccination (OR 2.21, 95% CI 1.47–3.32), with-
out statistically significant difference. Men in age groups that
could have been affected by universal vaccinations also had
increased chances to have a positive vaccination history (OR
1.68, 95% CI 1.61–1.75).
The random effect of countries was measured with the ICC
and was responsible for about 8% of the total variance of the
model (ICC = 0.08, 95% CI 0.05–0.12). We ran a sensitivity ana-
lysis excluding missing answers and participants who answered ‘I
don’t know’ which did not alter the magnitude or direction of
association much for most variables besides age group (<25: OR
1.39, 95% CI 1.34–1.44) and general vaccination programme
(age groups reached: OR 2.87, 95% CI 2.71–3.03). Full results
for sensitivity analysis can be found in Supplementary Table S2.
Discussion
We analysed the answers from a large dataset of MSM living in
Europe to determine what factors were associated with hepatitis
B vaccination coverage. Two country-level (MSM-specific vaccin-
ation recommendations and universal vaccination programmes)
and four individual-level (age, educational level, settlement size
and outness) covariates showed associations with the outcome
across descriptive, univariable and multivariable analyses, provid-
ing evidence for targeted public health actions.
Overall, 56.4% of participants had a positive history of vaccin-
ation in descriptive analysis. Data on hepatitis B vaccination
coverage among MSM in Europe are scarce and we only found
a few national studies for comparison. Estimates that were based
on serological proof ranged from 14% in a Danish study [33] to
30–38% in a Dutch study [34]. Another Dutch study, however,
found a self-reported vaccination rate of 50% [35], which is simi-
lar to our results for the Netherlands (54.4%). In the Danish study
participants also reported their vaccination rates, which were 18%
higher than results from blood tests showed [33]. We concluded
that our results are prone to recall bias and probably overestimate
actual vaccination rates. Confusion of vaccination against hepatitis
B with hepatitis A and a lack of knowledge about hepatitis could
be responsible for this effect.
Contrary to previous studies on MSM and factors that influ-
ence hepatitis B vaccination, we found a negative association
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Country n (%) n (%) n (%) n (%) n (%) n (%)
Austria 157 (3.8) 743 (18.2) 2294 (56.2) 299 (7.3) 37 (0.9) 555 (13.6)
Belarus 16 (4.4) 95 (25.9) 69 (18.8) 6 (1.6) 6 (1.6) 175 (47.7)
Belgium 293 (7.4) 784 (19.7) 1924 (48.3) 275 (6.9) 84 (2.1) 622 (15.6)
Bosnia & H. 12 (8.0) 40 (26.7) 35 (23.3) 3 (2.0) 2 (1.3) 58 (38.7)
Bulgaria 45 (4.3) 352 (34.0) 171 (16.5) 32 (3.1) 7 (0.7) 429 (41.4)
Croatia 18 (3.5) 190 (36.7) 155 (30.0) 28 (5.4) 5 (1.0) 121 (23.4)
Cyprus 11 (4.1) 60 (22.5) 117 (43.8) 17 (6.4) 4 (1.5) 58 (21.7)
Czech Republic 96 (4.0) 914 (38.1) 841 (35.0) 86 (3.6) 35 (1.5) 428 (17.8)
Denmark 89 (5.1) 665 (38.2) 571 (32.8) 103 (5.9) 10 (0.6) 304 (17.4)
Estonia 21 (3.5) 201 (33.8) 147 (24.8) 49 (8.2) 4 (0.7) 172 (29.0)
Finland 41 (2.0) 745 (36.8) 638 (31.5) 213 (10.5) 11 (0.5) 378 (18.7)
France 755 (6.8) 2251 (20.1) 4959 (44.4) 1170 (10.5) 308 (2.8) 1721 (15.4)
Germany 2738 (5.0) 10 644 (19.6) 28 453 (52.3) 3657 (6.7) 693 (1.3) 8202 (15.1)
Greece 178 (6.1) 673 (22.9) 1156 (39.3) 260 (8.8) 28 (0.9) 649 (22.0)
Hungary 58 (2.8) 816 (39.5) 650 (31.5) 131 (6.3) 8 (0.4) 404 (19.5)
Ireland 90 (4.1) 620 (28.2) 864 (39.4) 168 (7.7) 49 (2.2) 403 (18.4)
Italy 1353 (8.5) 3597 (22.5) 6315 (39.4) 715 (4.5) 253 (1.6) 3751 (23.5)
Latvia 62 (8.8) 272 (38.4) 193 (27.3) 37 (5.2) 3 (0.4) 141 (19.9)
Lithuania 33 (5.6) 269 (45.2) 87 (14.6) 29 (4.9) 2 (0.3) 175 (29.4)
Luxembourg 14 (5.0) 54 (19.3) 135 (48.2) 24 (8.6) 6 (2.1) 47 (16.8)
Malta 2 (1.7) 24 (20.2) 74 (62.2) 5 (4.2) 0 (0.0) 14 (11.7)
Moldova 7 (6.0) 26 (22.2) 23 (19.7) 1 (0.8) 7 (6.0) 53 (45.3)
Netherlands 435 (11.5) 648 (17.1) 2052 (54.2) 315 (8.3) 57 (1.5) 280 (7.4)
N. Macedonia 7 (6.0) 30 (25.6) 36 (30.8) 2 (1.7) 4 (3.4) 38 (32.5)
Norway 76 (3.6) 474 (22.6) 716 (34.2) 259 (12.4) 19 (0.9) 552 (26.3)
Poland 129 (4.7) 905 (32.9) 1103 (40.2) 191 (7.0) 12 (0.4) 406 (14.8)
Portugal 297 (5.7) 848 (16.3) 2774 (53.5) 311 (6.0) 103 (2.0) 854 (16.5)
Romania 127 (5.5) 759 (32.6) 504 (21.6) 95 (4.1) 33 (1.4) 809 (34.8)
Russia 309 (6.1) 1444 (28.7) 1267 (25.2) 276 (5.5) 90 (1.8) 1649 (32.7)
Serbia 65 (5.9) 429 (38.8) 149 (13.5) 31 (2.8) 9 (0.8) 423 (38.2)
Slovakia 24 (4.1) 247 (42.2) 146 (24.9) 16 (2.7) 9 (1.5) 144 (24.6)
Slovenia 30 (3.0) 452 (45.7) 256 (25.9) 35 (3.5) 4 (0.4) 213 (21.5)
Spain 998 (7.6) 3046 (23.2) 5395 (41.2) 817 (6.2) 134 (1.0) 2721 (20.8)
Sweden 113 (3.6) 931 (29.7) 1088 (34.7) 322 (10.3) 18 (0.6) 660 (20.1)
Switzerland 293 (5.8) 831 (16.5) 2751 (54.7) 310 (6.2) 90 (1.8) 753 (15.0)
Turkey 136 (7.5) 613 (33.9) 550 (30.5) 98 (5.4) 15 (0.8) 395 (21.9)
Ukraine 148 (8.6) 589 (34.4) 219 (12.8) 41 (2.4) 32 (1.9) 682 (39.9)
UK 946 (5.4) 3645 (20.6) 9002 (50.8) 1387 (7.8) 556 (3.1) 2182 (12.3)
EMIS-2010 10 222 (5.9) 39 926 (22.9) 77 879 (44.7) 11 814 (6.8) 2747 (1.6) 31 621 (18.1)
a‘No, I am naturally immune to hepatitis B (because I had it in the past)’.
b‘No, and I don’t know if I’m immune’.
c‘Yes, and I completed the course of three shots of vaccine’.
d‘Yes, but I did not complete the course of three shots of vaccine’.
e‘Yes, but I did not respond to the vaccines’.
f‘I don’t know’.
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Austria p – po po p
Belgium p po po (p)c p
Croatia – – pf pf p
Cyprus p pf – n –
Denmark p p(f) p(f) p(f) p
Estonia n po – po –
France p p(f) pc pc p
Germany p pf pf pf p
Greece n – pf pf –
Ireland p p(f) – pf p
Italy p pf pf pf p
Luxembourg n p(f) – pf –
Netherlands p pf pf pf p
N. Macedonia – – po po –
Norway p pf – pf –
Slovenia n p(f) pf pf –
Spain p pf n pf p
Sweden p p(f) n pc –
Switzerland – – – Pc p
Turkey – – n pc p
UK p pf pf pf p
Unclear countries Belarus – – – – –
Bosnia & H. – – po n –
Bulgaria p po n – n
Hungary n pf po n –




Czech Rep. – – – n –
Finland n n pc (p)f (p)
Latvia n n – n –
Lithuania n n – n –
Malta n n – po –
Moldova – – – (p)f –
Poland n n n po n
Portugal n n pc – n
Romania n – po n n
Russia – – – n –
Serbia – – n – –
Ukraine – – n n –
ECDC, European Centre for Disease Prevention and Control; ELPA, European Liver Patients’ Association; MSM, Men who have sex with men; VENICE, Vaccine European New Integrated
Collaboration Effort.
n = no MSM-specific vaccination recommendation; p = MSM-specific vaccination recommendation; (p) = MSM-specific vaccination recommendation implemented after the year 2010, treated
like no MSM-specific vaccination recommendation; – = no information.
c = co-payment required; f = free vaccination; (f) = free vaccination for some recipients; o = full out-of-pocket payment.
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between younger age and the outcome [7]. In multivariable ana-
lysis, however, men who could have been affected by universal
vaccination programmes had higher chances to have a positive
vaccination history and the effect was of similar magnitude as
that of MSM-specific vaccination recommendations. We found
that MSM with higher educational levels, who are living in bigger
settlements, and are out about their sexual orientation had higher
odds to be vaccinated against Hepatitis B. MSM who are better
educated and those living in big cities have easier access to health
care systems and gay-friendly health care providers in many
countries. Outness facilitates MSM to accept recommendations
that are directed specifically at them. An analysis with interactions
revealed that outness had an impact on vaccination history espe-
cially in older participants and younger men were vaccinated
regardless of their outness. This is probably explained by universal
vaccination programmes and the time of coming out.
Previous studies already showed that homonegative social and
legal climates obstructed access to prevention services and lead to
lower levels of precautionary behaviour regarding sexually trans-
mitted infections like HIV [36]. MSM in high-stigma countries
lacked control over possible infections and were therefore more
vulnerable towards HIV [6]. With this study we could show
that the same might be true for hepatitis B. The consequence
for public health and political measures should be to reduce
both stigmatisation of LGBTI (lesbian, gay, bisexual, trans and
intersex) citizens and to reinforce vaccinations for target
populations.
One of the strengths of our study is that we combined data
from various sources, extended by results from a self-provided
short survey, to measure the influence of hepatitis B vaccine
recommendations on the vaccination rates of MSM in Europe.
We were able to use a variable on national vaccination
recommendations that is backed up by a maximum of evidence.
While VENICE [13] and ELPA [14] named MSM specifically in
their reports, the ECDC [12] report named ‘multiple sex partners’
as key population. Our decision to use these key populations with
equal value was backed up by a high concordance between these
three reports and by findings from additional sources. The reports
from VENICE and ECDC were published around the same time
as EMIS took place. The report by ELPA on the other hand was
published in 2016 and changes in vaccination guidelines could
have happened in-between. However, results concurred largely
with data from our other sources and only for Finland we
found proof for implementation after the year 2010 [29].
For some countries like Malta, Poland and Romania most
sources negated a vaccination recommendation for MSM with
the exception of one source, respectively, that attested a recom-
mendation with full out-of-pocket payment for the recipient. It
is possible that these are two views of the same guideline by dif-
ferent health care professionals. The response from Russia to the
short survey highlighted another difficulty in vaccination guide-
line interpretation. Since 2001 a national programme offered
free vaccination against hepatitis B for all persons under the age
of 55 years. In countries where no specific programme for
MSM exists, but vaccination is recommended and available for
everyone free of charge, it remains unclear if target populations
are more encouraged to get vaccinated. Not naming a highly stig-
matised indication group like MSM in vaccination recommenda-
tions might even be beneficial for their vaccination rates [37].
Our synthesised results imply that 17 countries had either
clearly no recommendation for MSM or uncertainties regarding
their vaccination guidelines. Fourteen of these countries were in
the Eastern part of Europe, including Baltic countries, where vac-
cination rates were historically low [38]. It is possible that
Fig. 1. Map of Europe showing the classification of all 38 countries regarding their MSM-specific vaccination recommendations.
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underlying regional effects are in part responsible for the effect
that was attributed to vaccination recommendations and pro-
grammes in our analyses.
Participants from 10 European countries reported vaccination
rates above the EMIS average. Eight of these countries had imple-
mented MSM-specific vaccination recommendations. Malta and
Portugal are the two exceptions and their high rates despite a
lack of targeted programmes might be due to homopositive cli-
mates facilitating access to health services [39] and (in case of
Malta) the inherited system of genitourinary medicine clinics,
which appears highly effective for delivering quality sexual health
services [40].
Only about 20 660 (12.6%) participants from 18 countries
might have been vaccinated by a general vaccination programme
for infants or adolescents. Most of them (15 891) were from Italy,
Spain, Portugal and France, and their maximum age was 31 years.
Of these men, 58.9% reported a positive vaccination history which
was only slightly higher compared to remaining men in the
dataset (56.0%). This might be due to a lack of recall of childhood
vaccination. We recoded the item ‘No, and I don’t know if I’m
immune’ to ‘No vaccination history’. Our hypothesis was that of
men who answered ‘I don’t know’ the majority actually didn’t
receive a hepatitis B vaccination, they were true-negatives and vul-
nerable. Men reached by a universal vaccination programme or a
catch-up programme against hepatitis B in their childhood and
are not aware of it were recoded to ‘No vaccination history’ as
well. That means there could have been false-negatives who in
fact were protected. Thus, the true effect of universal programmes
could be higher than our results imply. Sensitivity analysis exclud-
ing men who didn’t know their vaccination status and missings
supported this assumption.
Limitations
Information on vaccination recommendations for key populations
was collected in all three examined reports and our own short
Table 3. Characteristics of EMIS participants by hepatitis B vaccination history
Characteristics
Total (N = 163 987)
Hepatitis B vaccination history
Yes (n = 92 440) No (n = 71 547)
N (%) n (%) n (%)
Age group:
< 25 40 211 (24.5) 21 818 (23.6) 18 393 (25.7)a
25–39 81 750 (49.9) 46 629 (50.4) 35 121 (49.1)
40 + 42 026 (25.6) 23 993 (26.0) 18 033 (25.2)
Educational level (6 levels of ISCEDb):
Low (ISCED 1,2) 13 002 (8.0) 6294 (6.9) 6708 (9.5)
Medium (ISCED 3,4) 68 705 (42.2) 37 998 (41.3) 30 707 (43.4)
High (ISCED 5,6) 81 004 (49.8) 47 657 (51.8) 33 347 (47.1)
Settlement size (number of inhabitants):
Medium-sized or smaller settlements (< 500 000) 87 972 (54.9) 47 790 (52.9) 40 182 (57.6)
Big to very big cities (500 000+) 72 167 (45.1) 42 620 (47.1) 29 547 (42.4)
Outness (being ‘out’ to family/friends/work or study colleagues):
No one 17 245 (10.6) 7684 (8.4) 9561 (13.5)
Few 34 992 (21.4) 16 725 (18.2) 18 267 (25.7)
Less than half 17 793 (10.9) 9584 (10.4) 8209 (11.5)
More than half 30 636 (18.8) 17 992 (19.6) 12 644 (17.8)
All or almost all 62 435 (38.3) 40 025 (43.5) 22 410 (31.5)
MSM-specific vaccination recommendation:
No or unclear recommendation 26 812 (16.3) 10 816 (11.7) 15 996 (22.4)
Payment requiredc 29 787 (18.2) 17 518 (18.9) 12 269 (17.1)
Free vaccination 107 388 (65.5) 64 106 (69.4) 43 282 (60.5)
General vaccination programme:
Not affected age groups 143 327 (87.4) 80 278 (86.8) 63 049 (88.1)
Age groups reached 20 660 (12.6) 12 162 (13.2) 8498 (11.9)
ISCED, International Standardised Classification of Educational Degrees; MSM, Men who have sex with men.
aχ2 test: P < 0.001 for all variables.
bSix levels of the ISCED, 1997 version.
cCo-payment or full out-of-pocket payment required.
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survey through questionnaires. Despite differences and insuffi-
ciencies in the 22 sources used, we rated the respective data as
equally valid. Inconsistencies in findings may be due to the fact
that the answers of contact persons rely on information provided
by different specialists. The number of sources we used is also not
exhaustive. More national guidelines or international reports on
vaccination programmes might have altered assignments of single
countries.
As EMIS was based on an online questionnaire only self-
reported vaccination rates could be analysed in this study. True
vaccination rates may be higher though, especially in younger
age groups, because they might have been vaccinated in early
years of their life and just were not aware of it. Vaccination
rates and all other variables derived from the EMIS-2010 dataset
were self-reported and thereby prone to recall bias, which could
also lead to an overestimation of actual vaccination rates.
Additionally, EMIS participants might have e.g. confused hepa-
titis A and B, for both of which vaccinations exist. However, ques-
tions on hepatitis A vaccination status or on knowledge about
hepatitis were not part of EMIS-2010.
The data analysed in this study are from 2010, and coverage
and associated factors may therefore have changed since then.
However, the follow-up EMIS-2017 data suggest that overall
there has been no substantial increase in vaccine uptake since
EMIS-2010 [41].
Conclusions
We provide the latest and most complete update on hepatitis B
vaccination recommendations for MSM in Europe. Differences
in national vaccination guidelines across European countries
affect vaccination rates and MSM in many parts of Europe are
still vulnerable to hepatitis B, even though vaccines are a widely
accessible way of protection. However, men who live in countries
with MSM-specific vaccination recommendations and homoposi-
tive societies have higher chances of being vaccinated against
hepatitis B.
Recommendations
Vaccination recommendations that target MSM specifically are
essential to increase vaccination coverage. The societal climate
for LGBTI citizens in Europe facilitating MSM to be out
about their sexual orientation should be further improved to
enable appropriate access to MSM-specific health care services.
A unified European approach is crucial in battling stigmata that
persist towards both sexually transmitted infections and sexual
minorities, in order to protect these vulnerable populations
from disease through united Public Health measures. Further
steps to increase vaccine uptake among MSM should be
investigated.
Table 4. Univariable and multivariable analysis of hepatitis B vaccination history
Variable Value Crude ORa (95% CI)
Adjusted ORb (95% CI)
n = 158 206
Age group <25 0.89 (0.87–0.92)c 0.94 (0.91–0.96)
25–39 ref. ref.
40+ 1.00 (0.98–1.03)d 0.94 (0.92–0.96)
Educational level Low (ISCEDe 1,2) ref. ref.
Medium (ISCED 3,4) 1.32 (1.27–1.37) 1.37 (1.32–1.43)
High (ISCED 5,6) 1.52 (1.47–1.58) 1.81 (1.74–1.89)
Settlement size
(number of inhabitants)
Medium-sized or smaller settlements (< 500 000) ref. ref.
Big to very big cities (500 000+) 1.21 (1.19–1.24) 1.23 (1.21–1.26)
Outness (being ‘out’ to family/
friends/work or study colleagues)
No one ref. ref.
Few 1.14 (1.10–1.18) 1.16 (1.11–1.20)
Less than half 1.45 (1.39–1.52) 1.31 (1.25–1.37)
More than half 1.77 (1.71–1.84) 1.50 (1.44–1.56)
All or almost all 2.22 (2.15–2.30) 1.76 (1.70–1.83)
MSM-specific vaccination recommendation No or unclear recommendation ref. ref.
Payment requiredf 2.11 (2.04–2.18) 1.96 (1.26–3.06)g
Free vaccination for MSM 2.19 (2.13–2.25) 2.21 (1.47–3.32)
General vaccination programme Not affected age groups ref. ref.
Age groups reached 1.12 (1.09–1.16) 1.68 (1.61–1.75)
CI, confidence interval; ISCED, International Standardised Classification of Educational Degrees; MSM, Men who have sex with men; OR, odds ratio; ref, reference.
aUnivariable logistic regression.
bMultilevel, multi-variable logistic regression with two levels (participants, countries).
cAll P-values < 0.001 except when marked otherwise.
dP-value 0.860.
eSix levels of the ISCED, 1997 version.
fCo-payment or full out-of-pocket payment required.
gP-value 0.003.
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Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268820000163.
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